Unknown NA INTERVENTIONAL 2-arm NCT00903292

Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma

Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung Adenocarcinoma

Sponsor: National Cheng-Kung University Hospital

Interventions erlotinib (Tarceva) pemetrexed (Alimta)

Updated 6 times since 2017 Last updated: May 15, 2009 Started: Mar 31, 2009 Primary completion: Apr 30, 2010 Completion: Dec 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Non-Small Cell Lung Cancer, this trial is ongoing. The trial is conducted by National Cheng-Kung University Hospital and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Dec 2025 — Present [monthly]

Unknown NA
Sep 2025 — Dec 2025 [monthly]

Unknown NA
Sep 2024 — Sep 2025 [monthly]

Unknown NA
Jul 2024 — Sep 2024 [monthly]

Unknown NA

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status NA

▶ Show 1 earlier version

Jan 2017 — Jan 2021 [monthly]

Unknown Status NA

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cheng-Kung University Hospital

Data source: National Cheng-Kung University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tainan, Taiwan